SecBot SecBot
8-K ·Filed Aug 14, 2026

VTGN

Vistagen Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001628280-26-056953
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The failed PALISADE-4 trial removes the primary near-term catalyst. The stock will likely remain under pressure until the FDA meeting outcome or a partnership/financing event. Given the limited cash runway, watch for dilutive financing or strategic alternatives. The very severe subgroup signal is weak and unlikely to support a standalone NDA.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

VTGN drug pipeline →

fasedienol

▼ Bearish Named in this 8-K
Impact
Phase
Phase 3 (completed — two of three Phase 3 trials failed)
Time to market
Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
Next catalyst
None dated

What to watchFasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.

Price Chart

Loading chart...

Executive Summary

Vistagen reported Q1 FY2027 net loss of $13.0M ($0.30/share), slightly missing the $0.29 consensus. Revenue of $1.5M was largely one-time from a Fuji Pharma agreement. The key negative is the failure of the PALISADE-4 Phase 3 trial for fasedienol in social anxiety disorder, with no clear path forward yet. Cash of $31.7M provides runway into 2027 but less than a year, raising financing risk.

Key Financial Metrics

EPS
−$0.30
est −$0.29 · -3.5%
Revenue
$1.5M
Rating
miss

Key Facts

  • Net loss per share $(0.30) vs consensus $(0.29), slight miss
  • Revenue $1.476M, primarily from one-time Fuji Pharma exclusivity expiration
  • PALISADE-4 Phase 3 trial for fasedienol failed primary endpoint; post-hoc subgroup signal only
  • Cash, cash equivalents, and marketable securities $31.7M as of June 30, 2026
  • Cash runway expected into 2027 but less than one year from now
  • FDA meeting planned for potential fasedienol registrational path
  • Cost-cutting measures implemented including March 2026 RIF

Financial Impact

Net loss of $13.0M for the quarter, cash burn ~$13.7M from $45.4M to $31.7M

cashnet lossrevenue

Risk Factors

  • Need for additional financing within 12 months, likely dilutive
  • FDA may not accept post-hoc subgroup data for registrational path
  • Further pipeline setbacks (itruvone, refisolone) could accelerate cash burn
  • Low institutional ownership and minimal analyst coverage limit support

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-056953
Document: vtgn-20260814.htm0001628280-26-056953
Document: 0001628280-26-056953-index-headers.html0001628280-26-056953
Document: 0001628280-26-056953-index.html0001628280-26-056953
Document: 0001628280-26-056953.txt0001628280-26-056953
8-K Data (Synthetic)0001628280-26-056953

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 Viewing No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026